WP
PEARW

Woodline Partners’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Woodline Partners’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,034
Closed -$70K – 773
2021
Q2 		$70K Buy
+50,034
New +$43.7K ﹤0.01% 524

Other funds holding PEARW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Woodline Partners's PEARW Position: Q3 2021 in Review

Woodline Partners sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q3 2021, closing a stake of 50,034 shares — an estimated $70K sold.

Woodline Partners first reported a position in PEARW in Q2 2021 and held it in 1 quarter. The position peaked at $70K in Q2 2021. 51 funds tracked by Wall St. Rank hold PEARW as of Q3 2021.

  • Woodline Partners reported no remaining Pear Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
  • Woodline Partners sold 50,034 Pear Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $70K.
  • Woodline Partners first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 1 quarter.
  • Woodline Partners's Pear Therapeutics, Inc. Warrant position peaked at $70K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q3 2021.

Based on Woodline Partners's 13F filing for Q3 2021, filed 15 Nov 2021.